NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NON-ALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NON-ALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in reversing dangerous liver scarring
Disease control CompletedThis study tested whether a weekly injection called pemvidutide could help people with a serious fatty liver disease called NASH. Researchers compared the drug to a placebo in 212 adults to see if it could reduce liver inflammation and scarring. The main goal was to see if the dr…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New injection shows promise in fighting fatty liver and obesity
Disease control CompletedThis study tested whether a weekly injection called survodutide could help adults with obesity and a serious fatty liver disease called NASH. Over 200 participants were randomly assigned to receive either the real medicine or a placebo (dummy injection) for 48 weeks, alongside di…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New pill tested to fight dangerous fatty liver disease
Disease control CompletedThis study tested whether a new oral drug called HSK31679 could improve liver health in people with NASH, a serious form of fatty liver disease that causes scarring. About 186 Chinese adults with confirmed NASH and moderate liver scarring took either the drug or a placebo pill da…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Early trial tests new Drug's effect on damaged livers
Disease control CompletedThis small, completed study tested whether a one-month course of an experimental drug called TRO19622 was safe and could improve liver health in people with NASH, a type of fatty liver disease. Twenty-two adults with confirmed NASH received either the drug or a placebo. The main …
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
First human test for liver disease drug begins
Knowledge-focused CompletedThis was the first study in humans for a potential new drug called AZD4076, which is being developed for a serious liver disease called NASH. The main goal was to check if single, increasing doses were safe and to see how the body processes the drug. It involved 40 healthy male v…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 02, 2026 03:40 UTC